ARPA-H announced teams for its THRIVE program—Treating Hereditary Rare Diseases with In Vivo prEcision genetic medicines—with a commitment of up to $160 million over five years. The initiative is designed to accelerate development and clinical trial deployment of in vivo precision genetic therapies across multiple technologies and trial designs for rare genetic pediatric conditions. The program’s launch adds momentum to a pipeline area that has been moving toward faster clinic translation, with emphasis on new study designs and deployment models that can support bespoke interventions. In parallel, other ARPA-H initiatives have been highlighted for targeted gene-editing acceleration. For developers and investors, THRIVE signals continued U.S. government support for individualized or precision genetic approaches, potentially reducing bottlenecks in IND-enabling work, early trial execution, and scaling manufacturing for rare-disease programs.